223 related articles for article (PubMed ID: 21211586)
41. Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.
Goldie SJ; O'Shea M; Diaz M; Kim SY
Reprod Health Matters; 2008 Nov; 16(32):86-96. PubMed ID: 19027626
[TBL] [Abstract][Full Text] [Related]
42. The impact of cytology screening and HPV vaccination on the burden of cervical cancer.
Tay K; Tay SK
Asia Pac J Clin Oncol; 2011 Jun; 7(2):154-9. PubMed ID: 21585695
[TBL] [Abstract][Full Text] [Related]
43. The potential cost-effectiveness of adding a human papillomavirus vaccine to the cervical cancer screening programme in South Africa.
Sinanovic E; Moodley J; Barone MA; Mall S; Cleary S; Harries J
Vaccine; 2009 Oct; 27(44):6196-202. PubMed ID: 19698807
[TBL] [Abstract][Full Text] [Related]
44. Cervical cancer in the human papillomavirus vaccination era.
Tay SK
Curr Opin Obstet Gynecol; 2012 Feb; 24(1):3-7. PubMed ID: 22123221
[TBL] [Abstract][Full Text] [Related]
45. An extended cost-effectiveness analysis of publicly financed HPV vaccination to prevent cervical cancer in China.
Levin CE; Sharma M; Olson Z; Verguet S; Shi JF; Wang SM; Qiao YL; Jamison DT; Kim JJ
Vaccine; 2015 Jun; 33(24):2830-41. PubMed ID: 25770785
[TBL] [Abstract][Full Text] [Related]
46. [Cost-effectiveness analysis on the once-in-a-lifetime cervical cancer screening program for women living in rural and urban areas of China].
Xu H; Zhao FH; Gao XH; Hu SY; Chen JF; Liu ZH; Xu XL; Gao LM; Liu QG; Ma L; Liu YJ; Qiao YL
Zhonghua Liu Xing Bing Xue Za Zhi; 2013 Apr; 34(4):399-403. PubMed ID: 23937850
[TBL] [Abstract][Full Text] [Related]
47. [Study on the value assessment of various screening programs regarding cervical cancer screening strategy in the rural areas of China].
Li LY; Qiao ZQ; Zhang MF; Yang JP; Bao YP; An YT; Lei J; Xiong NH; Yu XH; Zhang X; Pan QJ; Qiao YL
Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Oct; 28(10):964-7. PubMed ID: 18399140
[TBL] [Abstract][Full Text] [Related]
48. Prophylactic HPV vaccination for women over 18 years of age.
Adams M; Jasani B; Fiander A
Vaccine; 2009 May; 27(25-26):3391-4. PubMed ID: 19200838
[TBL] [Abstract][Full Text] [Related]
49. Vaccination against HPV: indications for women and the impact on the cervical screening programme.
Heideman DA; Snijders PJ; Berkhof J; Verheijen RH; Helmerhorst TJ; Meijer CJ
BJOG; 2008 Jul; 115(8):938-46. PubMed ID: 18651878
[TBL] [Abstract][Full Text] [Related]
50. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020-99: a modelling study.
Simms KT; Steinberg J; Caruana M; Smith MA; Lew JB; Soerjomataram I; Castle PE; Bray F; Canfell K
Lancet Oncol; 2019 Mar; 20(3):394-407. PubMed ID: 30795950
[TBL] [Abstract][Full Text] [Related]
51. Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China.
Levin CE; Sellors J; Shi JF; Ma L; Qiao YL; Ortendahl J; O'Shea MK; Goldie SJ
Int J Cancer; 2010 Sep; 127(6):1404-11. PubMed ID: 20049838
[TBL] [Abstract][Full Text] [Related]
52. Epidemiology and prevention of human papillomavirus and cervical cancer in sub-Saharan Africa: a comprehensive review.
Louie KS; de Sanjose S; Mayaud P
Trop Med Int Health; 2009 Oct; 14(10):1287-302. PubMed ID: 19772550
[TBL] [Abstract][Full Text] [Related]
53. [Integrating HPV testing for primary screening?].
Riethmuller D; Ramanah R; Pretet JL; Mougin C
J Gynecol Obstet Biol Reprod (Paris); 2008 Feb; 37 Suppl 1():S139-51. PubMed ID: 18191912
[TBL] [Abstract][Full Text] [Related]
54. Epidemiology of human papillomavirus infection and cervical cancer and future perspectives in Hong Kong, Singapore and Taiwan.
Tay SK; Ngan HY; Chu TY; Cheung AN; Tay EH
Vaccine; 2008 Aug; 26 Suppl 12():M60-70. PubMed ID: 18945415
[TBL] [Abstract][Full Text] [Related]
55. Human papillomavirus infection and cervical cancer prevention in Japan and Korea.
Konno R; Shin HR; Kim YT; Song YS; Sasagawa T; Inoue M; Park JS
Vaccine; 2008 Aug; 26 Suppl 12():M30-42. PubMed ID: 18945412
[TBL] [Abstract][Full Text] [Related]
56. Programmatic issues in the implementation of an HPV vaccination program to prevent cervical cancer.
Ault K; Reisinger K
Int J Infect Dis; 2007 Nov; 11 Suppl 2():S26-8. PubMed ID: 18162242
[TBL] [Abstract][Full Text] [Related]
57. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
Hristova L; Hakama M
Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
[TBL] [Abstract][Full Text] [Related]
58. [Vaccines against human papillomavirus (HPV); between registration and implementation].
van Rossum TG; de Melker HE; Houweling H; Voordouw AC; Meijer CJ; Helmerhorst TJ; Kretzschmar M; Berkhof J; van der Noordaa J
Ned Tijdschr Geneeskd; 2008 Apr; 152(17):987-92. PubMed ID: 18549172
[TBL] [Abstract][Full Text] [Related]
59. Domestic HPV vaccine price and economic returns for cervical cancer prevention in China: a cost-effectiveness analysis.
Zou Z; Fairley CK; Ong JJ; Hocking J; Canfell K; Ma X; Chow EPF; Xu X; Zhang L; Zhuang G
Lancet Glob Health; 2020 Oct; 8(10):e1335-e1344. PubMed ID: 32971056
[TBL] [Abstract][Full Text] [Related]
60. How will transitioning from cytology to HPV testing change the balance between the benefits and harms of cervical cancer screening? Estimates of the impact on cervical cancer, treatment rates and adverse obstetric outcomes in Australia, a high vaccination coverage country.
Velentzis LS; Caruana M; Simms KT; Lew JB; Shi JF; Saville M; Smith MA; Lord SJ; Tan J; Bateson D; Quinn M; Canfell K
Int J Cancer; 2017 Dec; 141(12):2410-2422. PubMed ID: 28801947
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
